ALKS Q1 2025 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$307M-12.5% YoY

Gross Profit

$257M83.9% margin

Operating Income

$14M4.5% margin

Net Income

$22M7.3% margin

EPS (Diluted)

$0.13

QoQ Revenue Growth

-28.7%

Cash Flow

Operating Cash Flow

$99M

Free Cash Flow

$89M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$570M

Stockholders' Equity

$1.5B

Cash & Equivalents

$400M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$307M	$350M	-12.5%
Gross Profit	$257M	$292M	-11.8%
Operating Income	$14M	$43M	-68.2%
Net Income	$22M	$37M	-39.0%

Revenue Segments

Product

$244M80%

Manufactured Product And Royalty

$62M20%